PDF(Pubmed)
Abstract：
Management of cancer during pregnancy requires careful consideration of risks and benefits from maternal and fetal perspectives. For advanced lung adenocarcinomas, with no targetable driver mutations, there is evidence-based guidance on the use of carboplatin-paclitaxel chemotherapy after first trimester. In contrast, for epidermal growth factor receptor (EGFR)-mutated or anaplastic lymphoma kinase (ALK)-rearranged metastatic lung adenocarcinomas, there is a paucity of clinical data on the safety of EGFR and ALK tyrosine kinase inhibitors to mother and fetus for official guidelines to recommend the use of these otherwise-first-line therapies in pregnancy. Considering this knowledge gap, we present a case of a young gravida 1 para 0 (G1P0) woman who continued alectinib 300 mg oral two times per day for ALK-rearranged metastatic lung adenocarcinoma throughout all 36 weeks of her pregnancy and delivered a healthy baby at term via caesarean section (C-section).
摘要：
怀孕期间癌症的管理需要从母体和胎儿的角度仔细考虑风险和益处。对于晚期肺腺癌，没有靶向驱动突变，妊娠早期后使用卡铂-紫杉醇化疗有循证指导.相比之下,对于表皮生长因子受体（EGFR）突变或间变性淋巴瘤激酶（ALK）重排的转移性肺腺癌，关于EGFR和ALK酪氨酸激酶抑制剂对母亲和胎儿的安全性的临床数据很少,官方指南建议在妊娠期间使用这些一线治疗.考虑到这种知识差距，我们介绍了1例年轻gravida1para0(G1P0)女性,她在妊娠36周期间继续口服alectinib300mg治疗ALK重排的转移性肺腺癌,每天2次,并在足月通过剖腹产(剖腹产)分娩了一个健康的婴儿.
